ஆண்டு நிதி அறிக்கை ஜனவரி ஜூன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆண்டு நிதி அறிக்கை ஜனவரி ஜூன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆண்டு நிதி அறிக்கை ஜனவரி ஜூன் Today - Breaking & Trending Today

Orion Oyj: Orion Corporation's financial reporting and Annual General Meeting in 2022

Orion Oyj: Orion Corporation's financial reporting and Annual General Meeting in 2022
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Eteläuomen Läi , Tuukka Hirvonen , Olli Huotari , Timo Lappalainen , Orion Corporation , Annual General Meeting , Financial Statement Release , Interim Reports , Half Year Financial Report , Report January March , Year Financial Report January June , Report January September , Financial Statements , Corporate Functions , Investor Relations , ஒரையந் நிறுவனம் , ஆண்டு ஜநரல் சந்தித்தல் , நிதி அறிக்கை வெளியீடு , இடைக்கால அறிக்கைகள் , பாதி ஆண்டு நிதி அறிக்கை , அறிக்கை ஜனவரி அணிவகுப்பு , ஆண்டு நிதி அறிக்கை ஜனவரி ஜூன் , அறிக்கை ஜனவரி செப்டம்பர் , நிதி அறிக்கைகள் , பெருநிறுவன செயல்பாடுகள் , முதலீட்டாளர் உறவுகள் ,

Investegate |Orion Oyj Announcements | Orion Oyj: Orion Group Interim Report 1-3/2021

Strong first quarter as exceptional circumstances continue
“In the early part of 2021, the exceptional circumstances brought on by the COVID-19 pandemic are still prevailing. For Orion, this means continuing to focus on looking after the health and safety of our employees and ensuring production continuity, product availability and patient safety in ongoing clinical trials.
In January–March 2021, Orion s net sales were EUR 269 (280) million and operating profit EUR 75 (84) million. As anticipated, they fell below the robust comparative period when the peak in demand for pharmaceuticals caused by the COVID-19 pandemic gave a boost to sales and profits. The Specialty Products unit had a good quarter even though due to the coronavirus pandemic and related restrictions implemented in various countries, the prevalence of seasonal illnesses such as the common flu has been lower than normal, and there has been a decline in non-critical procedures and medical appointments. Th ....

Eteläuomen Läi , United States , United Kingdom , Tuukka Hirvonen , Jari Karlson , Timo Lappalainen , Board Of Directors Orion Corporation , Orion Group Interim , Animal Health , Orion Corporation , Orion Group Interim Report , Groupinterim Report , Interim Report , Specialty Products , Year Financial Report January June , Report January September , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜரி கார்ல்சன் , பலகை ஆஃப் இயக்குநர்கள் ஒரையந் நிறுவனம் , ஒரையந் குழு இடைக்கால , விலங்கு ஆரோக்கியம் , ஒரையந் நிறுவனம் , ஒரையந் குழு இடைக்கால அறிக்கை , இடைக்கால அறிக்கை ,

Orion Oyj: Orion Group Interim Report 1-3/2021

Orion Oyj: Orion Group Interim Report 1-3/2021
Orion
1
This is a summary of Orion s Interim Report 1-3/2021. The complete report is attached to this stock exchange release and is available at https://www.orion.fi/en/Orion-group/investors/financial-reviews-and-presentations/
Net sales totalled EUR 269 million (EUR 280 million in 1-3/2020).
Operating profit was EUR 75 (84) million.
Profit before taxes was EUR 75 (83) million.
Equity ratio was 54% (69%).
ROCE before taxes was 38% (39%).
ROE after taxes was 35% (33%).
Basic earnings per share were EUR 0.42 (0.48).
Cash flow per share before financial items was EUR 0.19 (0.34).
The outlook for 2021 remains unchanged. Orion estimates that net sales in 2021 will be slightly lower than in 2020 (net sales in 2020 were EUR 1,078 million). Operating profit is estimated to be lower or clearly lower than in 2020 (operating profit in 2020 was EUR 280 million). ....

Eteläuomen Läi , United States , United Kingdom , Tuukka Hirvonen , Kostenloser Wertpapierhandel , Jari Karlson , Timo Lappalainen , Board Of Directors Orion Corporation , Orion Group Interim , Animal Health , Orion Corporation , Groupinterim Report , Interim Report , Specialty Products , Year Financial Report January June , Report January September , Investor Relations , Group Interim Report , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜரி கார்ல்சன் , பலகை ஆஃப் இயக்குநர்கள் ஒரையந் நிறுவனம் , ஒரையந் குழு இடைக்கால , விலங்கு ஆரோக்கியம் , ஒரையந் நிறுவனம் , இடைக்கால அறிக்கை ,

Investegate |Orion Oyj Announcements | Orion Oyj: Orion Group Financial Statement Release for 2020

Strong performance amid challenges brought on by COVID-19 pandemic
“The COVID-19 pandemic made 2020 an exceptional and demanding year for Orion and for the world. The strong spike in demand for pharmaceuticals seen in March and April brought challenges to Orion’s production and logistics. However, we prevailed due to the strong commitment and hard work of our people. We strived successfully – and will carry on striving – to ensure that pharmaceuticals manufactured and sold by Orion continue to be available to patients. Our current inventory status is good, but we need to keep working to this effect, as the risk of disruptions in global pharmaceutical supply chains remains higher than usual owing to the pandemic. In the current exceptional circumstances, we have prioritised looking after the health and safety of our employees and ensuring production continuity and patient safety in ongoing clinical trials, and we will continue to do so. Amidst the pandemic, we pushed ou ....

United States , United Kingdom , Eteläuomen Läi , Tuukka Hirvonen , Jari Karlson , Orion Dexdor , Timo Lappalainen , Orion Clevor , Orion Group , Orion Animal Health , Drug Administration , Orion Corporation , Board Of Directors Orion Corporation , Orion Group Financial Statement , Animal Health , Orion Group Financial Statement Release , Group Financial Statement Release , Financial Statement Release , Specialty Products , Senior Vice President , General Meeting , Report January March , Year Financial Report January June , Report January September , Financial Statements , Investor Relations ,

Orion Oyj: Orion Group Financial Statement Release for 2020

Orion Oyj: Orion Group Financial Statement Release for 2020
Orion Group Financial Statement Release for 2020
This is a summary or Orion s Financial Statement Release for 2020. The complete report is attached to this stock exchange release and is available at
https://www.orion.fi/en/Orion-group/investors/financial-reviews-and-presentations/
Net sales totalled EUR 1,078 million (EUR 1,051 million in 2019).
Operating profit was EUR 280 (253) million.
Net sales and operating profit include milestone payments amounting to EUR 42 (51) million.
Profit before taxes was EUR 278 (251) million.
Equity ratio was 67% (77%).
ROCE before taxes was 35% (30%).
ROE after taxes was 29% (26%).
Basic earnings per share were EUR 1.56 (1.43).
Cash flow per share before financial items was EUR 1.85 (1.68). ....

United States , United Kingdom , Eteläuomen Läi , Tuukka Hirvonen , Jari Karlson , Kostenloser Wertpapierhandel , Comtess Comtan , Orion Dexdor , Timo Lappalainen , Orion Clevor , Orion Group , Orion Animal Health , Drug Administration , Orion Corporation , Board Of Directors Orion Corporation , Orion Group Financial Statement , Animal Health , Group Financial Statement Release , Financial Statement Release , Specialty Products , Senior Vice President , General Meeting , Report January March , Year Financial Report January June , Report January September , Financial Statements ,